Effectiveness of PD-(L)1 inhibitors alone or in combination with platinum-doublet chmotherapy in first-line (1L) non-squamous non-small-cell lung cancer (Nsq-NSCLC) with PD-L1-high expression using real-world data. Ann Oncol. 2022 May;33(5):511-521....
[6] Perol, M., E. Felip, U. Dafni, et al., Effectiveness of PD-(L)1 inhibitors alone or in combination with platinum-doublet chemotherapy in first-line (1L) non-squamous non-small-cell lung cancer (Nsq-NSCL...
《实体肿瘤PD-L1免疫组织化学检测专家共识(2021 版)》指出,PD‐L1在肿瘤组织中的表达异质性会导致活检标本无法代表整个肿瘤的实际表达状态,肺癌、胃癌、乳腺癌及膀胱癌等多项研究结果提示,活检标本的取材数量、标本直径及标本内肿瘤细胞数量是影响活检与手术标本间PD...
PD-L1 expression was decreased in the samples from patients with AML with complete remission compared to that in patients with relapsed or refractory AML. In AML cell lines, glycolysis-associated genes ALDOA, PGK1, LDHA and HK2 were highly expressed in a PD-L1 high-expressed cell line. ...
The CHO/ Human PD-L1 Stable Cell Line was engineered to express full length human PD-L1 receptor (Gene ID: 29126), with different levels of PD-L1 expression (High, Medium, Low), which can be used to mimic cancer target cells with various PD-L1 expression levels. When co-cultured with...
[9] Munari E, Zamboni G, Lunardi G, et al. PD-L1 expression in non-small cell lung cancer: evaluation of the diagnostic accuracy of a laboratory-developed test using clone E1L3N in comparison with 22C3 and SP263 assays. Hum Pathol. 2019;90:54-59. doi:10.1016/j.humpath.2019.05.003...
PD-1/PD-L1相互作用作为非小细胞肺癌患者分层的预测性生物标志物,结合PD-L1表达,可以显著提高对免疫治疗的反应率。 SCI 12 March 2023 Functional Engagement of the PD-1/PD-L1 Complex But Not PD-L1 Expression Is Highly Predictive of Patient Response to Immunotherapy in Non–Small-Cell Lung Cancer ...
February 22, 2021 - The FDA has approved cemiplimab-rwlc monotherapy for use in the frontline treatment of patients with advanced non–small cell lung cancer with a PD-L1 expression level of 50% or higher. FDA The FDA has approved cemiplimab-rwlc (Libtayo) monotherapy for use in the ...
Only patients with both high PD-L1 expression and high immune infiltration could benefit from chemotherapy plus immunotherapy in first-line treatment of advanced NSCLC. For patients lacking either PD-L1 expression or immune infiltration, chemotherapy alone might be a better treatment option to avoid un...
英文摘要: OBJECTIVE:To ev aluate the economics of pembrolizumab versus first-line chemotherapy in the treatment of advanced non-small cell lung cancer with high programmed cell death protein ligand 1(PD-L1)expression from the perspective of Chinese healthcare system. METHODS :Published KEYNOTE- 042...